Xtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above Two Hundred Day Moving Average of $0.00

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.68. Xtant Medical shares last traded at $0.67, with a volume of 41,584 shares traded.

Wall Street Analysts Forecast Growth

Separately, BTIG Research increased their target price on shares of Xtant Medical from $2.00 to $3.00 and gave the stock a “buy” rating in a report on Thursday, May 16th.

Xtant Medical Trading Down 4.8 %

The company has a quick ratio of 0.98, a current ratio of 2.34 and a debt-to-equity ratio of 0.35. The firm has a market cap of $80.90 million, a P/E ratio of -62.10 and a beta of 0.38.

Xtant Medical (NYSEAMERICAN:XTNT) last released its earnings results on Wednesday, May 15th. The medical device company reported ($0.03) EPS for the quarter. Xtant Medical had a negative net margin of 1.64% and a negative return on equity of 3.60%. The company had revenue of $27.87 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xtant Medical stock. Juniper Investment Company LLC purchased a new stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 348,399 shares of the medical device company’s stock, valued at approximately $408,000. Xtant Medical accounts for about 0.2% of Juniper Investment Company LLC’s investment portfolio, making the stock its 10th biggest position. Juniper Investment Company LLC owned 0.27% of Xtant Medical as of its most recent filing with the Securities and Exchange Commission. 69.33% of the stock is currently owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.